Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes

Abstract : Brain butyrylcholinesterase (BChE) is an attractive target for drugs designed for the treatment of Alzheimer's disease (AD) in its advanced stages. It also potentially represents a biomarker for progression of this disease. Based on the crystal structure of previously described highly potent, reversible, and selective BChE inhibitors, we have developed the fluorescent probes that are selective towards human BChE. The most promising probes also maintain their inhibition of BChE in the low nanomolar range with high selectivity over acetylcholinesterase. Kinetic studies of probes reveal a reversible mixed inhibition mechanism, with binding of these fluorescent probes to both the free and acylated enzyme. Probes show environment-sensitive emission, and additionally, one of them also shows significant enhancement of fluorescence intensity upon binding to the active site of BChE. Finally, the crystal structures of probes in complex with human BChE are reported, which offer an excellent base for further development of this library of compounds.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.univ-grenoble-alpes.fr/hal-02864342
Contributeur : Frank Thomas <>
Soumis le : jeudi 11 juin 2020 - 08:59:44
Dernière modification le : mercredi 15 juillet 2020 - 13:04:02

Lien texte intégral

Identifiants

Collections

Citation

Stane Pajk, Damijan Knez, Urban Košak, Maja Zorović, Xavier Brazzolotto, et al.. Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes. Journal of Enzyme Inhibition and Medicinal Chemistry, Informa Healthcare, 2020, 35 (1), pp.498-505. ⟨10.1080/14756366.2019.1710502⟩. ⟨hal-02864342⟩

Partager

Métriques

Consultations de la notice

39